American Heart Journal
Volume 146, Issue 2 , Pages 199-202 , August 2003

Inflammation in atherosclerosis: causal or casual? The need for randomized trials

  • Karen Meir, MD

      Affiliations

    • Department of Pathology, Hadassah University Hospital, Jerusalem, Israel
    • Center for Research, Prevention, and Treatment of Atherosclerosis, Hadassah University Hospital, Jerusalem, Israel
    • ,
  • Eran Leitersdorf, MD

      Affiliations

    • Center for Research, Prevention, and Treatment of Atherosclerosis, Hadassah University Hospital, Jerusalem, Israel
    • Department of Medicine B, Hadassah University Hospital, Jerusalem, Israel
    • Corresponding Author InformationReprint requests: Eran Leitersdorf, MD, Department of Medicine B, Hadassah University Hospital, Kiryat Hadassah, PO Box 12221, Jerusalem 91120, Israel.
    • ,
  • Charles H. Hennekens, MD

      Affiliations

    • Mount Sinai Medical Center—Miami Heart Institute and Departments of Medicine & Epidemiology and Public Health, University of Miami School of Medicine, Miami, Fla, USA

References 

  1. Hennekens CH, Buring JE. Epidemiology in medicine. Boston: Little, Brown and Co; 1987;
  2. Glass CK, Witztum JL. Atherosclerosis (the road ahead). Cell. 2001;104:503–516
  3. Ross R. Atherosclerosis (an inflammatory disease). N Engl J Med. 1999;340:115–126
  4. Navab M, Berliner JA, Watson AD, et al.  The yin and yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol. 1996;16:831–842
  5. Ritchie ME. Nuclear factor-κB is selectively and markedly activated in humans with unstable angina pectoris. Circulation. 1998;98:1707–1713
  6. Ikonomidis I, Andreotti F, Economou E, et al.  Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100:793–798
  7. Ridker PM, Cushman M, Stampfer MJ, et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  8. Ridker PM, Hennekens CH, Buring JE, et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Engl J Med. 2000;342:836–843
  9. Mallat Z, Besnard S, Duriez M, et al.  Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999;85:e17–24
  10. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:1876–1890
  11. Metzler B, Mayr M, Dietrich H, et al.  Inhibition of arteriosclerosis by T-cell depletion in normocholesterolemic rabbits immunized with heat shock protein 65. Arterioscler Thromb Vasc Biol. 1999;19:1905–1911
  12. Zhou X, Nicoletti A, Elhage R, et al.  Transfer of CD4+ T cells aggravates atherosclerosis in immunodeficient apoE knockout mice. Circulation. 2000;102:2919–2922
  13. Hebert PR, Gaziano JM, Chan KS, et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 1997;278:313–321
  14. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712–1719
  15. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al.  Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687–692
  16. Sparrow CP, Burton CA, Hernandez M, et al.  Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001;21:115–121
  17. Albert M, Danielson E, Rifai N, et al.  Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE) (a randomized trial cohort study). JAMA. 2001;286:64–70
  18. Ridker PM, Rifai N, Rose L, et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  19. Hennekens CH, Buring JE, Sandercock P, et al.  Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989;80:749–756
  20. Paul A, Calleja L, Camps J, et al.  The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sci. 2000;68:457–465
  21. Cyrus T, Sung S, Zhao L, et al.  Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation. 2002;106:1282–1287
  22. Nielsen VG, Webster RO. Inhibition of human polymorphonuclear leukocyte functions by ibuprofen. Immunopharmacology. 1987;13:61–71
  23. Zapolska-Downar D, Naruszewicz M, Zapolski-Downar A, et al.  Ibuprofen inhibits adhesiveness of monocytes to endothelium and reduces cellular oxidative stress in smokers and non-smokers. Eur J Clin Invest. 2000;30:1002–1010
  24. Stuhlmeier KM, Li H, Kao JJ. Ibuprofen (new explanation for an old phenomenon). Biochem Pharmacol. 1999;57:313–320
  25. Thurberg BL, Collins T. The nuclear factor-κB/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol. 1998;9:387–396
  26. Amberger A, Hala M, Saurwein-Teissl M, et al.  Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins. Mol Med. 1999;5:117–128
  27. Stoller DK, Grorud CB, Michalek V, et al.  Reduction of atherosclerosis with nonsteroidal anti-inflammatory drugs. J Surg Res. 1993;54:7–11
  28. Pratico D, Tillman C, Zhang ZB, et al.  Acceleration of atherogenesis by Cox-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A. 2001;98:1158–1163
  29. Linos A, Worthington JW, O’Fallon W, et al.  Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis (a long-term follow-up study). Mayo Clin Proc. 1978;53:581–586
  30. Sajadieh A, Wendelboe O, Hansen JF, et al.  Nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Am J Cardiol. 1999;83:1263–1265
  31. Ko D, Wang Y, Berger AK, et al.  Nonsteroidal antiinflammatory drugs after acute myocardial infarction. Am Heart J. 2002;143:475–481
  32. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology. 2000;11:382–387
  33. Stemme V, Swedenborg J, Claesson H, et al.  Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg. 2000;20:146–152
  34. Bombardier C, Laine L, Reicin A, et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med. 2000;343:1520–1528
  35. Catella-Lawson F, McAdam B, Morrison BW, et al.  Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735–741
  36. Cheng Y, Austin S, Rocca B, et al.  Role of prostacyclin in the cardiovascular response to Thromboxane A2. Science. 2002;296:539–541
  37. Patrono C, Coller B, Dalen JE, et al.  Platelet-active drugs (the relationships among dose, effectiveness, and side effects). Chest. 2001;119(1 Suppl):39–63S
  38. Catella-Lawson F, Reilly MP, Kapoor SC, et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809–1817
  39. Konstam MA, Weir MR, Reicin A, et al.  Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104:2280–2288
  40. Kazmi SM, Plante RK, Visconti V, et al.  Suppression of NF kappa B activation and NF kappa B-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase. J Cell Biochem. 1995;57:299–310
  41. Lee WM, Lee KT, Reiner JM. Effects of naproxen and methotrexate on the extent of aortic lesions and cholesterol concentrations in cholesterol-fed rabbits. Exp Mol Pathol. 1980;33: 349–342
  42. Amann R, Peskar BA. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol. 2002;447:1–9
  43. Van Hecken A, Schwartz JI, Depre M, et al.  Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000;40:1109–1120
  44. Catella-Lawson F, Reilly MP, Kapoor SC, et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809–1817
  45. Altman R, Luciardi HL, Muntaner J, et al.  Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation (the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study). Circulation. 2002;106:191–195
  46. Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 1998;97:1095-102
  47. Hennekens CH. Clinical and research challenges in risk factors for cardiovascular diseases. Eur Heart J 2000;21:1917–21
  48. Eidelman RS, Lamas GA, Hennekens CH. The new National Cholesterol Education Program guidelines (clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease). Arch Intern Med. 2002;162:2033–2036

PII: S0002-8703(03)00226-6

doi: 10.1016/S0002-8703(03)00226-6

American Heart Journal
Volume 146, Issue 2 , Pages 199-202 , August 2003

Article Tools